At what administration frequency is Mepolizumab (Nucala) given?

Mepolizumab, marketed under the brand name Nucala, is administered as a subcutaneous injection typically once every 4 weeks. This frequency is determined by the drug's pharmacokinetics and its therapeutic purpose in managing conditions such as severe asthma and eosinophilic granulomatosis with polyangiitis. Administering Mepolizumab every 4 weeks ensures adequate maintenance of its therapeutic effects while minimizing the potential for side effects associated with more frequent dosing. This regimen supports the drug's role in reducing exacerbations and improving overall disease control for patients with elevated eosinophil levels. The specified dosing schedule aligns with clinical guidelines and the drug's approved prescribing information. Other frequencies, such as daily or every two weeks, do not reflect the established guidelines or the pharmacologic profile of Mepolizumab.